Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) are observed in 15–20% of breast cancers (HER2+ breast cancers), and anti-HER2 therapies have significantly improved prognosis of patients with HER2+ breast cancer. One resistance mechanism to anti-HER2 therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Yumi, Morita, Tomoko Yamamori, Ohashi, Akihiro, Haeno, Hiroshi, Hakozaki, Yumi, Fujii, Masanori, Kashima, Yukie, Kobayashi, Susumu S., Mukohara, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729878/
https://www.ncbi.nlm.nih.gov/pubmed/33303839
http://dx.doi.org/10.1038/s41598-020-78646-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729878/
https://www.ncbi.nlm.nih.gov/pubmed/33303839
http://dx.doi.org/10.1038/s41598-020-78646-y

Ejemplares similares